Skip to main content
. 2017 Jul 12;199(4):1465–1475. doi: 10.4049/jimmunol.1602151

FIGURE 1.

FIGURE 1.

NADA reduces circulating IL-6, CCL2, and PAI-1 levels and increases survival in endotoxemic mice. (A–C) WT mice were challenged i.v. with LPS or carrier and immediately thereafter were treated i.v. with NADA (1, 5, or 10 mg/kg) or vehicle. Levels of IL-6 (A), CCL2 (B), and PAI-1 (C) were quantified in plasma after 2 h (n = 4 mice per group). *p < 0.05 LPS-treated mice in the presence or absence of NADA, Mann–Whitney U test. (D) Survival was followed over a 48-h period in WT mice challenged i.p. with LPS (7 mg/kg) and treated with two i.v. doses of NADA (5 mg/kg) or carrier at t = 5 min and 2 h (n = 41 mice per group). *p < 0.0287, log-rank test.